Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the approvals for drug production and registration for Low Calcium Peritoneal Dialysis Solution (Bicarbonate-G1.5%), Peritoneal Dialysis Solution (Bicarbonate-G2.5%), Peritoneal Dialysis Solution (Bicarbonate-G4.25%) and Low Calcium Peritoneal Dialysis Solution (Bicarbonate-G4.25%) (the "Products") from the National Medical Products Administration of China (the "NMPA"), all being in 2000ml specification, under type 3 chemical drug and regarded as passing the consistency evaluation. Among which, Low Calcium Peritoneal Dialysis Solution (Bicarbonate-G4.25%) is the third of such approvals for the PRC entities. The Products mainly used for peritoneal dialysis in patients with chronic renal failure, especially when hypermagnesemia has not been adequately improved.

The Group has a strategic focus on the field of renal replacement therapy, with products covering peritoneal dialysis solution, hemofiltration replacement fluid and others. The four peritoneal dialysis solutions approved this time are all with bicarbonate buffer system and dual-chamber bag, employing a design of isolated storage of different components and immediate mixing before use, resulting in a complex manufacturing process and a relatively high technological barrier. With 1.5%/2.5%/4.25% glucose concentrations as well as standard and low-calcium formulas, the Products can meet the clinical needs of patients with different conditions as well as combined calcium and magnesium abnormalities. As a new and upgraded product in the peritoneal dialysis field, with a limited number of approved manufacturers in China, the Products have a favorable competitive landscape, and a differentiated pricing potential compared to traditional lactate preparations. With increasing clinical awareness, there will be ample room for its market penetration.

With this approval, the Group has established a leading and complete peritoneal dialysis solution product portfolio in China, covering multiple technical routes and specifications of lactate and bicarbonate. Leveraging the Group's mature intravenous infusion technology platform, stable production and quality control can be achieved. As an important treatment for end-stage renal disease, peritoneal dialysis offers the convenience of home-based operation and flexible scheduling. It can be used complementarily and sequentially with hemodialysis to prolong patient survival, resulting a robust the clinical demand. Compared to hemodialysis, peritoneal dialysis market penetration rate has a more significant room for improvement in China, indicating a promising future for growth. This approval will further improve the Group's renal dialysis pipeline and enhance its competitiveness in renal replacement therapy segment.

In addition, the Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Arginine Hydrochloride Injection (200ml:20g) from the NMPA, being the second of such approvals for the PRC entities, under type 3 chemical drug and regarded as passing the consistency evaluation. It is mainly used for emergency to reduce blood ammonia concentration when oral formulations cannot control acute exacerbations of hyperammonemia in certain diseases.

The Group continues its layout of emergency and critical care treatment pipeline. This approved Arginine Hydrochloride Injection (200ml:20g) is a large-volume therapeutic infusion. Compared to widely used small-volume ampoule formulations as of now, this product does not require clinical dilution, making it convenient for use in emergency and critical care scenarios. This approval further enriches the Group's therapeutic infusion product line.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 19 November 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Meng Guo, Mr. Chow Hing Yeung, Ms. Qu Wanrong and Mr. Wu Hengyao as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.